Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events

Summary

This study is being carried out to study the efficacy and safety of treatment with melagatran injection followed by ximelagatran tablets in preventing blood clots, compared with enoxaparin for a period of 5-6 weeks. A separate visit, independent from the study will be done approximately 6 months after the surgery.

Timeline

Start

2005-09

Primary completion

2006-08

Completion

2006-08

Outcome

Outcome not reported

Stopped: “Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety.”

Publications

• Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, Mouret P, Rosencher N, Andersson M, Bylock A, Jensen E, Boberg B; EXTEND Study Group. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. 2009;123(3):488-97. doi: 10.1016/j.thromres.2008.02.017. Epub 2008 May 15.

Drugs

Indications